Abstract
Groundbreaking progress has been recently made in elucidating the signaling pathways that are altered in adrenocortical carcinoma (ACC), an endocrine malignancy that still has an unfavorable prognosis, and in understanding its genomic structure. These advances need now to be translated to create cellular and animal models more relevant to human disease in order to develop new and more effective diagnostic procedures and targeted therapies against this deadly malignancy.
Trial registration:
ClinicalTrials.gov NCT01898715.
MeSH terms
-
Adrenal Cortex Neoplasms / diagnosis*
-
Adrenal Cortex Neoplasms / drug therapy*
-
Adrenal Cortex Neoplasms / genetics
-
Adrenocortical Carcinoma / diagnosis*
-
Adrenocortical Carcinoma / drug therapy*
-
Adrenocortical Carcinoma / genetics
-
Animals
-
Biomarkers, Tumor / genetics*
-
Clinical Trials as Topic
-
Congresses as Topic
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
MicroRNAs / genetics
-
Signal Transduction
-
Sterol O-Acyltransferase / antagonists & inhibitors
Substances
-
Biomarkers, Tumor
-
Enzyme Inhibitors
-
MicroRNAs
-
Sterol O-Acyltransferase
-
sterol O-acyltransferase 1
Associated data
-
ClinicalTrials.gov/NCT01898715